This video highlights results of a study that examined predictors for unplanned hospital readmissions in patients with hematologic malignancies.
In this video, Sudipto Mukherjee, MD, MPH, of the Cleveland Clinic in Ohio, discusses results of a study that examined predictors for unplanned hospital readmissions in patients with hematologic malignancies.
Results of the study (abstract 532) were presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT
June 2nd 2025Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.